





ANALYSIS OF USAGE PROFILE, EFFECTIVENESS AND SAFETY OF ALIROCUMAB **IN A TERTIARY HOSPITAL**

Mondelo García C, Fernández Bargiela N, Fernández Oliveira C, Balea Filgueiras J, Giménez Arufe V, Martín Herranz MI. Pharmacy Service. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 84. 15006 A Coruña, Spain.

Background

- * Hypercholesterolaemia is a common and growing health problem, above all in developed countries, which can cause serious consequencies in patients who suffer from it.
- Alirocumab is a mondegraded inside cells, increasing their number in the surface of cells to join with LDL cholesterol and remove it from blood.oclonal antibody that blocks a protein called PCSK9 and prevents LDL cholesterol receptors being absorbed and and degraded inside cells, increasing their number in the surface of cells to join with LDL

Objective

Our objective is to analyse the use, effectiveness and safety of alirocumab in a tertiary level hospital.

Methods

Observational retrospective study of all patients treated with alirocumab from 1 December 2016 to 1 October 2017.


Data sources: electronic prescription program and electronic medical records. * Main variables: sex, age, cause of statins' failure, previous clinical trial, alirocumab dose, adverse effects and LDL cholesterol levels after 3 months treatment.





		All patients included in the study were instructed in the correct use of the dispositive of alirocumab in the first visit to the hospital pharmacy		% patients 10% 84% 6%
 ✓ 50 patients ✓ 66% male ✓ Mean age: 60 ± 11.5 years-old 		16 patients were previously treated with anti-PCSK9 in clinical trials	All of them contin adequate levels cholester	s of LDL
<u>30% patients</u> Start treatment with alirocumab due to the ineffectiveness of statins	<u>20% patients</u> Start treatment with alirocumab because of statins intolerance	All patients who started alirocumab treatment during the study period	se effects Number of patients	
			Rinitis 4 Arrhoea 2	

Muscle symptoms



of LDL cholesterol



Alirocumab constitutes an effective, safe and well-tolerated alternative to decreased LDL cholesterol to adequate levels when patients are intolerant to statins or when statins are ineffective.

